Akinyemi Oni-Orisan, PharmD, PhD | The Center for Health and Community

Associate Professor

P_Clinical Pharmacy

+1 415 502-7551

The long-term research goal of Dr. Oni-Orisan’s lab is to improve pharmacological regimens for the prevention and treatment of cardiovascular disease in diverse populations through precision medicine. To accomplish this objective, his group combines computational approaches in pharmacogenomics and pharmacoepidemiology using electronic health record-linked biobanks. His lab is currently funded to investigate genetic determinants of efficacy and safety for statin therapy in diverse populations.

Dr. Oni-Orisan teaches and mentors pharmacy students in the Discovery Projects research program including leading the inaugural Health Disparities Discovery Group.

Dr. Oni-Orisan serves as Diversity Leader for the Department of Clinical Pharmacy to champion diversity, equity and inclusion (DEI) efforts in the department.

Publications

Cytochrome P450 2D6 17 and 29 Allele Activity for Risperidone Metabolism: Advancing Precision Medicine Health Equity.

Clinical pharmacology and therapeutics

Kehinde O, Vaughn SE, Amaeze O, Toren P, Retke B, Oni-Orisan A, Ramsey LB

Statin Initiation and Dementia Incidence in a Large Health Care System From 1997 to 2020: A Target Trial Emulation Study.

Neurology

Zimmerman SC, Choi M, Jiang C, Ferguson EL, Hoffmann TJ, Swinnerton K, Oni-Orisan A, Gilsanz P, Meyers TJ, Choudhary V, Whitmer RA, Risch N, Krauss RM, Schaefer CA, Glymour MM

Progress in Pharmacogenomics Implementation in the United States: Barrier Erosion and Remaining Challenges.

Clinical pharmacology and therapeutics

Smith DM, Douglas MP, Aquilante CL, Deverka PA, Devine B, Dunnenberger HM, Empey PE, Hertz DL, Monte AA, Moyer AM, Patel JN, Pratt VM, Saulsberry L, Scott SA, Voora D, Woodahl EL, Whirl-Carrillo M, Oni-Orisan A, Pharmacogenomics Global Research Network (PGRN) Publications Committee

Uncertainty in the estimated effects of statin initiation on risk of dementia: using a multiverse analysis to assess sources of variability.

European journal of epidemiology

Ferguson EL, Zimmerman SC, Jiang C, Choi M, Meyers TJ, Hoffmann TJ, Gilsanz P, Wang J, Oni-Orisan A, Whitmer RA, Risch N, Krauss RM, Patel CJ, Schaefer CA, Glymour MM

Response to "Comment on 'Independent associations of high-density lipoprotein cholesterol and triglyceride levels with Alzheimer's disease and related dementias' ".

Alzheimer's & dementia : the journal of the Alzheimer's Association

Ferguson EL, Hoffmann TJ, Oni-Orisan A, Risch N, Krauss RM, Schaefer CA, Glymour M

Empowering Early-Career Scientists: Opportunities Through ASCPT Programs, Networks, and Communities.

Clinical pharmacology and therapeutics

Sharma S, Gerhart J, Minichmayr IK, Strydom N, Maglalang PD, Liao M, Long T, Tang Girdwood S, Oni-Orisan A, Nakhla K, Li D

MIR192 Upregulates GLP-1 Receptor and Improves Statin-Induced Impairment of Insulin Secretion.

bioRxiv : the preprint server for biology

Kuang YL, Locatelli CAA, Qin Y, Zhang Y, Theusch E, Muñoz-Howell A, Sanchez G, Lu M, Nguyen MA, Yalamanchili T, Wang X, Nalula G, Mattis AN, Oni-Orisan A, Iribarren C, Krauss RM, Mulvihill EE, Medina MW

SLCO1B1 Functional Variants, Bilirubin, Statin-Induced Myotoxicity, and Recent Sub-Saharan African Ancestry: A Precision Medicine Health Equity Study.

Clinical pharmacology and therapeutics

Haldar T, Kvale M, Yang J, Douglas MP, Coyote-Maetas W, Kachuri L, Witte JS, Iribarren C, Medina MW, Krauss RM, Yee SW, Oni-Orisan A

Sociodemographic modifiers of effects of statin initiation on dementia incidence: An emulated trial design in a large health care member population with 10+ years of follow-up.

Alzheimer's & dementia : the journal of the Alzheimer's Association

Choi M, Zimmerman SC, Jiang C, Wang J, Swinnerton K, Hoffmann TJ, Oni-Orisan A, Ferguson EL, Meyers T, Choudhary V, Whitmer RA, Risch N, Krauss RM, Schaefer CM, Glymour MM, Gilsanz P

Independent associations of high-density lipoprotein cholesterol and triglyceride levels with Alzheimer's disease and related dementias.

Alzheimer's & dementia : the journal of the Alzheimer's Association

Ferguson EL, Zimmerman SC, Jiang C, Choi M, Meyers TJ, Hoffmann TJ, Gilsanz P, Oni-Orisan A, Wang J, Whitmer RA, Risch N, Krauss RM, Schaefer CA, Glymour MM

Design and implementation of an action plan for justice, equity, diversity, and inclusion within the Clinical Genome Resource.

American journal of human genetics

Popejoy AB, Ritter DI, Azzariti D, Berg JS, Bulkley JE, Cho M, Gonzaga-Jauregui C, Klein TE, Martschenko DO, Oni-Orisan A, Ramos EM, Rehm HL, Riggs ER, Wright MW, Yudell M, Plon SE, Morales J

Characterizing the genetic architecture of drug response using gene-context interaction methods.

Cell genomics

Sadowski M, Thompson M, Mefford J, Haldar T, Oni-Orisan A, Border R, Pazokitoroudi A, Cai N, Ayroles JF, Sankararaman S, Dahl AW, Zaitlen N

X chromosome dosage drives statin-induced dysglycemia and mitochondrial dysfunction.

Nature communications

Zhang P, Munier JJ, Wiese CB, Vergnes L, Link JC, Abbasi F, Ronquillo E, Scheker K, Muñoz A, Kuang YL, Theusch E, Lu M, Sanchez G, Oni-Orisan A, Iribarren C, McPhaul MJ, Nomura DK, Knowles JW, Krauss RM, Medina MW, Reue K

Preferences and Perspectives of Black Male Barbershop Patrons on Receiving Health Care in Nontraditional Settings.

Health equity

Chong S, Huynh B, Wong S, Woldeyesus T, Faulks M, El-Amin K, Thibeaux J, Lewis J, Harlin R, Carter M, Shatara R, Zhou C, Oni-Orisan A

SLCO1B1 functional variants and statin-induced myopathy in people with recent genealogical ancestors from Africa: a population-based real-world study.

medRxiv : the preprint server for health sciences

Yee SW, Haldar T, Kvale M, Yang J, Douglas MP, Oni-Orisan A

Low- and High-Density Lipoprotein Cholesterol and Dementia Risk Over 17 Years of Follow-up Among Members of a Large Health Care Plan.

Neurology

Ferguson EL, Zimmerman SC, Jiang C, Choi M, Swinnerton K, Choudhary V, Meyers TJ, Hoffmann TJ, Gilsanz P, Oni-Orisan A, Whitmer RA, Risch N, Krauss R, Schaefer CA, Glymour MM

Metformin Cessation and Dementia Incidence.

JAMA network open

Zimmerman SC, Ferguson EL, Choudhary V, Ranatunga DK, Oni-Orisan A, Hayes-Larson E, Duarte Folle A, Mayeda ER, Whitmer RA, Gilsanz P, Power MC, Schaefer C, Glymour MM, Ackley SF

An Introductory Tutorial on Cardiovascular Pharmacogenetics for Healthcare Providers.

Clinical pharmacology and therapeutics

Oni-Orisan A, Tuteja S, Hoffecker G, Smith DM, Castrichini M, Crews KR, Murphy WA, Nguyen NHK, Huang Y, Lteif C, Friede KA, Tantisira K, Aminkeng F, Voora D, Cavallari LH, Whirl-Carrillo M, Duarte JD, Luzum JA, Pharmacogenomics Global Research Network (PGRN) Publications Committee

Gene expression in African Americans, Puerto Ricans and Mexican Americans reveals ancestry-specific patterns of genetic architecture.

Nature genetics

Kachuri L, Mak ACY, Hu D, Eng C, Huntsman S, Elhawary JR, Gupta N, Gabriel S, Xiao S, Keys KL, Oni-Orisan A, Rodríguez-Santana JR, LeNoir MA, Borrell LN, Zaitlen NA, Williams LK, Gignoux CR, Burchard EG, Ziv E

Development and application of an algorithm for statin-induced myopathy based on electronic health record-derived structured elements.

medRxiv : the preprint server for health sciences

Oni-Orisan A, Lu M, Peng JA, Krauss RM, Iribarren C, Medina MW

Advancing CYP2D6 Pharmacogenetics Through a Pharmacoequity Lens.

Clinical pharmacology and therapeutics

Kehinde O, Ramsey LB, Gaedigk A, Oni-Orisan A

Diversity in Clinical Pharmacology: A Call to Action.

Clinical pharmacology and therapeutics

Brown K, Etrouth S, Jayachandran P, Moore J, Oni-Orisan A, Vasist L, Zheng S, Zhou Z, Dresser M

A large genome-wide association study of QT interval length utilizing electronic health records.

Genetics

Hoffmann TJ, Lu M, Oni-Orisan A, Lee C, Risch N, Iribarren C

Polygenic risk score and statin relative risk reduction for primary prevention of myocardial infarction in a real-world population.

Clinical pharmacology and therapeutics

Oni-Orisan A, Haldar T, Cayabyab MAS, Ranatunga DK, Hoffmann TJ, Iribarren C, Krauss RM, Risch N

Modest effect of statins on fasting glucose in a longitudinal electronic health record based cohort.

Cardiovascular diabetology

Haldar T, Oni-Orisan A, Hoffmann TJ, Schaefer C, Iribarren C, Krauss RM, Medina MW, Risch N

Perceptions of Older Men Using a Mobile Health App to Monitor Lower Urinary Tract Symptoms and Tamsulosin Side Effects: Mixed Methods Study.

JMIR Human Factors

Wang EY, Breyer BN, Lee AW, Rios N, Oni-Orisan A, Steinman MA, Sim I, Kenfield SA, Bauer SR

Tracking Lower Urinary Tract Symptoms and Tamsulosin Side Effects Among Older Men Using a Mobile App (PERSONAL): Feasibility and Usability Study.

JMIR formative research

Lee AW, Kenfield SA, Wang EY, Enriquez A, Oni-Orisan A, Steinman MA, Sim I, Breyer BN, Bauer SR

QT Interval Dynamics and Cardiovascular Outcomes: A Cohort Study in an Integrated Health Care Delivery System.

Journal of the American Heart Association

Mantri N, Lu M, Zaroff JG, Risch N, Hoffmann T, Oni-Orisan A, Lee C, Jorgenson E, Iribarren C

Torsade de pointes: A nested case-control study in an integrated healthcare delivery system.

Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc

Mantri N, Lu M, Zaroff JG, Risch N, Hoffmann T, Oni-Orisan A, Lee C, Iribarren C

Advancing Precision Medicine Through the New Pharmacogenomics Global Research Network.

Clinical pharmacology and therapeutics

Giacomini KM, Karnes JH, Crews KR, Monte AA, Murphy WA, Oni-Orisan A, Ramsey LB, Yang JJ, Whirl-Carrillo M

Effect of SLCO1B1 T521C on Statin-related Myotoxicity with Use of Lovastatin and Atorvastatin.

Clinical pharmacology and therapeutics

Lu B, Sun L, Seraydarian M, Hoffmann TJ, Medina MW, Iribarren C, Krauss RM, Risch N, Oni-Orisan A

Leveraging innovative technology to generate drug response phenotypes for the advancement of biomarker-driven precision dosing.

Clinical and translational science

Oni-Orisan A, Srinivas N, Mehta K, Lohy Das J, Nguyen TT, Tison GH, Bauer SR, Burian M, Funk RS, Graham RA

Embracing Genetic Diversity to Improve Black Health.

The New England journal of medicine

PERSONAL: Feasibility Study Protocol for Placebo-Controlled, Randomized n-of-1 Trials of Tamsulosin for Lower Urinary Tract Symptoms.

Frontiers in Digital Health

Bauer SR, Breyer BN, Oni-Orisan A, Steinman MA, Sim I, McCulloch CE, Kenfield SA

The impact of adjusting for baseline in pharmacogenomic genome-wide association studies of quantitative change.

npj Genomic Medicine

Oni-Orisan A, Haldar T, Ranatunga DK, Medina MW, Schaefer C, Krauss RM, Iribarren C, Risch N, Hoffmann TJ

Assessing the clinical impact of CYP2C9 pharmacogenetic variation on phenytoin prescribing practice and patient response in an integrated health system.

Pharmacogenetics and genomics

Fohner AE, Ranatunga DK, Thai KK, Lawson BL, Risch N, Oni-Orisan A, Jelalian AT, Rettie AE, Liu VX, Schaefer CA

Characterization of Statin Low-Density Lipoprotein Cholesterol Dose-Response Using Electronic Health Records in a Large Population-Based Cohort.

Circulation. Genomic and precision medicine

Oni-Orisan A, Hoffmann TJ, Ranatunga D, Medina MW, Jorgenson E, Schaefer C, Krauss RM, Iribarren C, Risch N